Rising Trends of Giving Birth in Hospitals and Increasing Count of Caesarian Procedures are Fueling the Growth of the Oxytocic Pharmaceuticals Market during the Forecast Period 2022-2027

The Oxytocic Pharmaceuticals Market size is estimated to reach $139.5 million by 2027, growing at a CAGR of 7.4% over the forecast period 2022-2027. The growth of the oxytocic pharmaceuticals market is greatly fueled by the rising trend of giving birth in hospitals and the increasing count of cesarean procedures. Oxytocic medicines are utilized in obstetrics for a variety of purposes like initiation of labor, labor arrest movement, contraction stress testing, labor management and the treatment of uterine atony and postpartum hemorrhage. The medication may be applied to terminate the embryo in case of premature delivery. The application of oxytocic medications at the time of a cesarean section is a vital interference to avert uterine atony or treat entrenched postpartum hemorrhage. Synthetic oxytocin is extensively utilized in maternity care across the world. Natural oxytocin is made by extracting it from the pituitary glands of animals. Oxytocin is accessible as tablets and injectables.

Oxytocic Pharmaceuticals Market Growth Drivers:

Surging Applications of Oxytocic Pharmaceuticals:

Synthetic oxytocin is marketed under the brand names such as Pitocin. Synthetic oxytocin derivatives are manmade medicines. Oxytocin tablets and injectables are readily available in today's market. Considering induction or stimulation of labor, the initial dose needs to be 0.5-1 mU/min (equal to 3-6 ml of the dilute Oxytocic solution per hour). Oxytocic agents are medicines that encourage uterine action and are utilized to cause labor, boost contractions, decrease the hazard of postpartum hemorrhage instantly consequent to birth and discharge fetal contents in incomplete abortion. Endogenous oxytocic medications are also provided usually succeeding C-sections to avert the growth of uterine atony. Oxytocic agents are provided as intravenous or intramuscular injections to treat postpartum hemorrhage, labor initiation and incomplete or inevitable abortion. The surging applications of Oxytocic Pharmaceuticals are therefore driving the growth of the Oxytocic Pharmaceuticals Industry, thereby contributing to the Oxytocic Pharmaceuticals Industry Outlook.

Soaring Advantages of Oxytocin are Propelling the Growth of the Oxytocic Pharmaceuticals Market:

Natural oxytocin is a uterine stimulant. Natural oxytocin is a hormone generated in the hypothalamus. Oxytocin tablets and injectables are procurable. Oxytocin is a hormone and a neurotransmitter. It accounts for contractions at the time of labor, for breast milk letdown and for erection. It is accountable for positive emotions like trust and happiness. The hormone also causes bonding between the mother and the baby. Investigations demonstrate that mothers with soaring levels of oxytocin during pregnancy and the earliest month consequent to birth bond more with their babies than those with lesser quantities. The standard solution for infusion includes 10 milliunits of oxytocin/mL. Oxytocin possesses a calming impact and may impact the emotions and mental health of a person. The soaring advantages of oxytocin are therefore propelling the growth of the Oxytocic Pharmaceuticals Market.

Equity Investment:

In April 2022, Zentalis Pharmaceuticals declared that it had consented to sell 953,834 of its common shares at a price of $26.21 per share to Pfizer for gross amount of $25.0 million (the “Transaction”). The common shares were provided and sold to Pfizer in a registered direct offering organized without an underwriter or placement agent. 

Oxytocic Pharmaceuticals Market: Competitive Landscape

To request for a quote, provide your details in the below link:

https://www.industryarc.com/reports/request-quote?id=17449